ArticleHeliyon2024
Bibliometric analysis of global research on human organoids.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Organoids at the forefront of global health: accelerated research and ethical implications in the cases of Zika and COVID-19.Global public health · 2025Article
- Interpretation of the past, present, and future of organoid technology: an updated bibliometric analysis from 2009 to 2024.Frontiers in cell and developmental biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence and rapid development of human organoids have provided the possibility to replace animal models in treating human diseases. Intelligence studies help focus on research hotspots and address key mechanistic issues. Currently, few comprehensive studies describe the characteristics of human organoid research. In this study, we extracted 8,591 original articles on organoids from the Web of Science core collection database over the past two decades and conducted intelligence analysis using CiteSpace. The number of publications in this field has experienced rapid growth in the last ten years (almost 70-fold increase since 2009). The United States, China, Germany, Netherlands, and UK have strong collaborations in publishing articles. Clevers Hans, Van Der Laan, Jason R Spence, and Sato Toshiro have made significant contributions to advancing progress in this field. Clustering and burst analysis categorized research hotspots into tissue model and functional construction, intercellular signaling, immune mechanisms, and tumor metastasis. Organoid research in highly cited articles covers four major areas: basic research (38%), involving stem cell developmental processes and cell-cell interactions; biobanking (10%), with a focus on organoid cultivation; precision medicine (16%), emphasizing cell therapy and drug development; and disease modeling (36%), including pathogen analysis and screening for disease-related genetic variations. The main obstacles currently faced in organoid research include cost and technology, vascularization of cells, immune system establishment, international standard protocols, and limited availability of high-quality clinical trial data. Future research will focus on cost-saving measures, technology sharing, development of international standards, and conducting high-level clinical trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.